Organisation paid for research Program year 2025 Source: CMS Open Payments

Qualmedica Research LLC

Neither a doctor nor a teaching hospital

Research payments

$9,409,383

1,053 payments

Through program year 2025, Qualmedica Research LLC is reported as receiving $9,409,383 in research payments, across 1,053 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $882,981 44
2024 Research $1,192,723 278
2023 Research $1,208,995 269
2022 Research $1,165,099 157
2021 Research $3,314,092 148
2020 Research $627,271 94
2019 Research $1,018,223 63

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $7,300,655 245 payments
  2. Novartis Pharmaceuticals Corporation $501,483 5 payments
  3. GlaxoSmithKline, LLC. $287,121 100 payments
  4. Janssen Research & Development, LLC $241,754 28 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $205,332 158 payments
  6. Supernus Pharmaceuticals, Inc. $204,269 36 payments
  7. Pfizer Inc. $146,947 51 payments
  8. Acrotech Biopharma LLC $123,284 12 payments
  9. Dermavant Sciences, Inc. $114,295 367 payments
  10. Shire North American Group Inc $95,405 25 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $1,520,459 8 payments
  2. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $1,386,374 8 payments
  3. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $456,064 5 payments
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $387,241 6 payments
  5. A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $307,461 6 payments
  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $307,165 14 payments
  7. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $304,322 9 payments
  8. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $296,134 10 payments
  9. A Two-Year, Phase III Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 MG S.C. Secukinumab Versus Placebo, in Combination With Soc Therapy, in Patients With Active Lupus Nephritis $295,930 2 payments
  10. A Phase 3, 12 Month, Open Label Study of Lasmiditan in Pediatric Patients With Migraine Pioneer Peds2 $253,741 18 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record